Eledon reports Phase 2 BESTOW kidney transplant data
Eledon Pharmaceuticals (NASDAQ:ELDN) reported extension data showing a 12 mL/min kidney function advantage at 18 months.
Eledon Pharmaceuticals (NASDAQ:ELDN) reported extension data showing a 12 mL/min kidney function advantage at 18 months.
Clinical-stage biopharmaceutical firm Traws Pharma (NASDAQ:TRAW) updated guidance for its influenza prophylaxis program to enable a planned Phase 2a trial.
Workforce solutions provider Atlantic International (NASDAQ:ATLN) reported first-quarter 2026 revenue of $249.9 million.
Biopharmaceutical firm Nuvectis (NASDAQ:NVCT) licensed exclusive ex-China rights for two clinical drug assets in a deal valued up to $1.461 billion.
Biotechnology firm bioAffinity Technologies (NASDAQ:BIAF) announced preclinical findings showing its novel small interfering RNA therapeutic approach selectively destroys cells from two common skin cancers that affect an estimated 5.4 million annual United States cases.
Booz Allen Hamilton (NYSE:BAH) executed a definitive agreement to acquire Ultra I&C Mission Solutions for $720 million to expand its defense technology portfolio.
Worksport (NASDAQ:WKSP) announced a preliminary gross margin of approximately 35% for the month of May 2026.
Outdoor Holding Company (NASDAQ:POWW) reported a 10.1% increase in fourth-quarter revenue to $13.9 million.
Palvella Therapeutics (NASDAQ:PVLA) announced that the FDA granted rolling review for its rare genetic disease drug application.
Organon (NYSE:OGN) finalized a global licensing agreement with Sebela Pharmaceuticals for a hormone-free birth control device that is 99% effective.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy